Are SRI’s new pharmaceutical or biotechnology discoveries available for use by patients, either through clinical trials or some other means?
SRI Biosciences’ research focuses on basic disease mechanisms, drug discovery, and preclinical development of new therapeutics, vaccines, and other biomedical products. We have worked with the National Institutes of Health and many pharmaceutical and biotechnology companies for more than 50 years. We have helped develop several SRI drugs that have entered clinical trials (research studies conducted with patients), and several more SRI drugs are undergoing preclinical evaluation in the laboratory. Marketed examples of these drugs include bexarotene and halofantrine. SRI has also helped its government and industry partners advance more than 100 drugs into clinical trials and more than 30 drugs onto the market. SRI itself does not typically conduct clinical trials, and our research samples are neither ready for nor appropriate for human use. When SRI discoveries are ready for clinical trials, and sometimes even earlier in the research process, we seek partners such as pharmaceutical or bi
